AGM/EGMJun 5, 2026, 04:24 PM
Zevra Therapeutics Stockholders Elect Directors; Board Declassification Fails
AI Summary
Zevra Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 4, 2026. Stockholders elected Douglas W. Calder and Corey Watton as Class II directors and ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. However, a proposal to amend the Company's Restated Certificate of Incorporation to phase out the classified Board structure and provide for annual director elections did not receive the required affirmative vote of more than 66 2/3% of outstanding common stock.
Key Highlights
- Douglas W. Calder elected as Class II director with 25,754,763 votes For.
- Corey Watton elected as Class II director with 29,878,306 votes For.
- Ernst & Young LLP ratified as independent auditor with 45,947,281 votes For.
- Proposal to declassify the Board failed, receiving 32,557,653 votes For.
- Board declassification required over 66 2/3% of 59,114,850 outstanding shares.
- 46,326,616 shares, or 78.37% of outstanding stock, were voted at the meeting.
Price Impact
More from ZVRA